| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCR5 |
| Uniprot No | P32302 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-55aa |
| 氨基酸序列 | MNYPLTLEMDLENLEDLFWELDRLDNYNDTSLVENHLCPATEGPLMASFKAVFVP |
| 预测分子量 | 19.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCR5重组蛋白的3篇参考文献示例(内容为虚构，供参考)：
---
1. **文献名称**：*Expression and functional characterization of recombinant human CXCR5 in B cell migration*
**作者**：Smith A, et al.
**摘要**：本研究通过哺乳动物表达系统成功制备了功能性重组CXCR5蛋白，并验证其与配体CXCL13的结合活性。实验表明，重组CXCR5在体外可介导B细胞的定向迁移，为研究淋巴组织发育和免疫调节提供了工具。
---
2. **文献名称**：*Structural insights into CXCR5 activation using purified recombinant protein*
**作者**：Lee J, et al.
**摘要**：作者利用昆虫细胞系统表达并纯化CXCR5重组蛋白，通过冷冻电镜解析其与CXCL13结合后的三维结构，揭示了受体激活的关键构象变化，为靶向CXCR5的药物设计提供了结构基础。
---
3. **文献名称**：*Recombinant CXCR5 as a tool for screening antiviral compounds*
**作者**：Wang X, et al.
**摘要**：研究构建了稳定表达重组CXCR5的HEK293细胞系，用于高通量筛选靶向CXCR5的抗病毒小分子。实验发现部分化合物可有效阻断CXCL13-CXCR5信号通路，为治疗相关病毒感染提供了潜在策略。
---
4. **文献名称**：*Role of recombinant CXCR5 in T follicular helper cell differentiation*
**作者**：Garcia R, et al.
**摘要**：通过体外表达重组CXCR5蛋白，研究证实其在Tfh细胞分化中的关键作用。CXCL13/CXCR5信号轴通过激活下游MAPK通路促进免疫突触形成，为自身免疫疾病的机制研究提供了新方向。
---
以上文献摘要围绕CXCR5重组蛋白的表达、结构、功能及应用展开，涵盖基础研究与转化医学领域。
**Background of CXCR5 Recombinant Protein**
CXCR5 (C-X-C chemokine receptor type 5), also known as Burkitt lymphoma receptor 1 (BCA-1 receptor), is a G protein-coupled receptor (GPCR) that plays a critical role in immune cell trafficking and lymphoid tissue organization. It is primarily expressed on B lymphocytes, follicular helper T cells (Tfh), and some dendritic cells. CXCR5 binds specifically to the chemokine CXCL13. which is produced in lymphoid organs and inflammatory sites. This interaction guides the migration of immune cells to B-cell-rich areas, such as germinal centers in lymph nodes, facilitating adaptive immune responses like antibody production and memory cell formation.
Recombinant CXCR5 protein is engineered using heterologous expression systems (e.g., mammalian cells, insect cells, or *E. coli*) to produce soluble or membrane-bound forms for research applications. The protein typically retains functional domains, including seven transmembrane helices, extracellular loops for ligand binding, and intracellular regions for G-protein coupling. Tags (e.g., His, FLAG) are often added to aid purification and detection.
CXCR5 is implicated in various diseases. Dysregulation of the CXCL13/CXCR5 axis is linked to autoimmune disorders (e.g., rheumatoid arthritis, lupus), chronic inflammation, and cancers like B-cell lymphomas. Recombinant CXCR5 serves as a tool to study receptor-ligand interactions, screen therapeutic inhibitors, or develop antibodies. It is also used in functional assays (e.g., chemotaxis, calcium flux) to dissect signaling pathways and evaluate drug efficacy.
Recent studies highlight its potential as a biomarker or therapeutic target, particularly in modulating pathological immune responses. Advances in structural biology, such as cryo-EM, have further elucidated CXCR5’s activation mechanisms, aiding rational drug design. Overall, recombinant CXCR5 remains pivotal in immunology and oncology research, bridging basic science and clinical applications.
×
